SIA-IgG confers poor prognosis and represents a novel therapeutic target in breast cancer.

Zhang, Man; Zheng, Jinhua; Guo, Junying; Zhang, Qiujin; Du, Juan; Zhao, Xiangfeng; Wang, Zhihua; Liao, Qinyuan

Zhang, Man; Zheng, Jinhua; Guo, Junying; Zhang, Qiujin; Du, Juan; Zhao, Xiangfeng; Wang, Zhihua; Liao, Qinyuan.

Afiliación

Zhang M; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Zheng J; Department of Pathology, Guilin Medical University Affiliated Hospital, Guilin, Guangxi province, China.
Guo J; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Zhang Q; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Du J; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Zhao X; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Wang Z; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.
Liao Q; Department of Immunology, Guilin Medical University, Guilin, Guangxi province, China.

Bioengineered ; 13(4): 10072-10087, 2022 04.

Article en En | MEDLINE | ID: mdl-35473571

Asunto(s)

Neoplasias de la Mama; Anticuerpos Monoclonales/uso terapéutico; Neoplasias de la Mama/metabolismo; Femenino; Humanos; Inmunoglobulina G; Pronóstico; Vía de Señalización Wnt

Palabras clave

Wnt/ß-catenin signaling pathway; breast caicinoma; cancer therapy; non B-IgG; survival

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Bioengineered Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google